Study S001971

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM)- Semaglutide v DPP4 Inhibitors

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record Study Protocol and Statistical Analysis Plan (PDF)

Registration

Registration: NCT05768945
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 742670
Start: 2022-11-30
Primary completion: 2023-07-07
Lead sponsor: Brigham and Women's Hospital
Conditions: Diabetes
Interventions: DRUG:Semaglutide; DRUG:DPP-4 inhibitor
Results posted: TRUE

Registered primary outcomes

Time to Dementia Onset [Median follow up times: 1) 98 days (exp), 134 days (ref) 2) 118 days (exp), 132 days (ref) 3) 90 days (exp), 308 days (ref) 4) 99 days (exp), 135 days (ref)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.